NEWS COMMENTARY

University of Pittsburgh develops microneedle-based vaccine for COVID-19

Published:
April 06, 2020
Coverage:
Digital Transformation More...
Activities:
Research
by Danielle Bradnan
Very important

While there are significant benefits to this approach, including the potential to mail vaccines to at-risk populations for home vaccination, there have been no trials verifying the efficacy of any microneedle-based vaccine in preventing disease. Despite years of research, the closest use case for microneedle drug delivery in humans has been for the flu vaccine, which has only undergone Phase I clinical trials and not demonstrated the prevention of disease – only efficacy in eliciting an immune response. Clients should not look to the microneedle approach as a viable COVID-19 vaccine in the short term but should consider investing in the technology for its significant value proposition in reducing risk in the vaccine supply chain.

For the original news article, click here .


Further Reading

Otsuka partners with Click Therapeutics to develop a new digital therapeutic to treat depression

News Commentary | January 08, 2019

Click Therapeutics, a digital therapeutic developer, will partner with Otsuka to develop a digital therapeutic to treat major depressive disorder (MDD). This comes just months after Otsuka announced its collaboration with Proteus Digital Health on its ingestible sensor pill platform. Otsuka isn't ... Not part of subscription

Heterocyclic lipids conjugated to mRNA vaccines increase anti-tumor efficacy

News Commentary | October 01, 2019

A team at the Koch Institute for Integrative Cancer Research and the Massachusetts Institute of Technology identified lipid nanoparticles that not only aid in the delivery of scalable RNA vaccines but also act as adjuvants, boosting a vaccine's effectiveness. This is a solution to an ongoing issue ... To read more, click here.

Pirbright Institute engineers synthetic antibodies to combat avian influenza

News Commentary | April 06, 2020

Using genetic engineering, scientists at The Pirbright Institute have developed single‑chain variable‑fragment antibodies (scFvs) against the H9N2 strain of avian influenza. In lab testing, the scFvs bound to proteins on the outside of H9N2, preventing it from invading the host cell. However, the ... Not part of subscription